Stopped: As a part of portfolio and planning reassessment for the current period, a decision has been made to prioritize, optimize and reallocate resources. As a result, enrollment and other study activities have been temporarily paused.
This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Baseline demographics and clinical characteristics
Timeframe: At inclusion
Pre-inclusion relapse history
Timeframe: From NMOSD diagnosis to inclusion (retrospective baseline)
Pre-inclusion NMOSD-related hospitalizations
Timeframe: From NMOSD diagnosis to inclusion (retrospective baseline)
Time from first symptoms to NMOSD diagnosis
Timeframe: From first NMOSD symptoms to date of diagnosis (retrospective baseline)
Prior misdiagnoses profile
Timeframe: From first NMOSD symptoms to confirmed NMOSD diagnosis (retrospective baseline)
AQP4-IgG testing method
Timeframe: At time of NMOSD diagnostic workup (retrospective baseline)
MRI brain T2-hyperintense lesion count change
Timeframe: Baseline (≤12 months pre-inclusion) and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Optic nerve MRI findings
Timeframe: Baseline (≤12 months pre-inclusion) and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Spinal cord MRI lesion metrics
Timeframe: Baseline (≤12 months pre-inclusion) and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Relapse prevention therapy patterns
Timeframe: From NMOSD diagnosis to inclusion and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Acute relapse treatment modalities
Timeframe: From NMOSD diagnosis to inclusion and Months 6, 12, 18, 24, 30, and 36 post-inclusion
Concomitant medications
Timeframe: From NMOSD diagnosis to inclusion and Months 6, 12, 18, 24, 30, and 36 post-inclusion